Company Profile
ACADIA Pharmaceuticals Inc. Stock Price, News & Analysis
- Ticker:
- ACAD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
28.45 USD (-1.22%)
Close
Last updated: August 6, 2026
3.58B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ACAD closed down 1.22% at $28.45. No new same-company headline was identified in the current news window.
Company overview
Business overview
Acadia Pharmaceuticals is a biopharmaceutical company focused on neuroscience and rare disease, with commercial products in areas such as psychosis and movement disorders. Its business combines marketed therapies with a pipeline aimed at CNS and specialty indications.
Geographic Base and Sector Classification
Acadia is headquartered in the United States and listed on NASDAQ. It sits in specialty neuroscience biopharma.
Business Model Characteristics
The company depends on product sales, launch execution, and pipeline expansion across CNS and rare disease. Investors watch revenue growth, label breadth, and development milestones.
Position Within the Biotechnology Landscape
Acadia occupies a strong specialty-neuroscience niche within biotech. It has more commercial footing than a typical development-stage company, but still reacts to pipeline and launch developments.
Future catalysts
Acadia’s catalysts are DAYBUE execution, near-term CNS franchise updates, and any label / commercial step that broadens the company’s growth base. The company’s value depends on turning its CNS assets into a more durable franchise.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ACADIA Pharmaceuticals Inc. (ACAD)?
ACADIA Pharmaceuticals Inc. (ACAD) most recently closed at 28.45 USD, a -1.22% move versus the previous session.
What is the market cap of ACADIA Pharmaceuticals Inc. (ACAD)?
ACADIA Pharmaceuticals Inc. currently has a market capitalization of 3.58B USD on BioPharmSignal.
What does ACADIA Pharmaceuticals Inc. do?
Acadia Pharmaceuticals is a biopharmaceutical company focused on neuroscience and rare disease, with commercial products in areas such as psychosis and movement disorders. Its business combines marketed therapies with a pipeline aimed at CNS and specialty indications.
On which exchange is ACAD stock listed?
ACADIA Pharmaceuticals Inc. (ACAD) is associated with NASDAQ, United States, Biopharma.
What is Acadia?
Acadia’s catalysts are DAYBUE execution, near-term CNS franchise updates, and any label / commercial step that broadens the company’s growth base.
Which conditions is ACADIA Pharmaceuticals Inc. targeting with Acadia?
ACADIA Pharmaceuticals Inc. is associated with rare disease, neuroscience based on its company overview and current catalyst commentary.
How does ACADIA Pharmaceuticals Inc. describe recent progress with Acadia?
Acadia’s catalysts are DAYBUE execution, near-term CNS franchise updates, and any label / commercial step that broadens the company’s growth base.
What is Pharmaceuticals?
Acadia Pharmaceuticals is a biopharmaceutical company focused on neuroscience and rare disease, with commercial products in areas such as psychosis and movement disorders.